Related Experiment Video
Updated: Dec 22, 2025

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
[Multifactor predictive model in patients with myocardial infarction based on modern biomarkers]
A F Khamitova1, I A Lakman2, R R Akhmetvaleev2
1Bashkir State Medical University.
Insights
New biomarkers, including N-terminal pro-brain natriuretic peptide (NT-proBNP), ST2, and Pentraxin-3 (Ptx-3), significantly improve the prediction of cardiovascular complications in patients with myocardial infarction (MI). This multifactorial model aids in remote risk assessment.
Area of Science:
- Cardiology
- Biomarker Research
- Predictive Modeling
Background:
- Acute coronary syndrome remains a leading cause of mortality and morbidity in the Russian Federation.
- Serum biomarkers like NT-proBNP, ST2, and Ptx-3 offer enhanced diagnostic and risk stratification capabilities for cardiovascular complications (CVC).
Purpose of the Study:
- To investigate the prognostic value of current serum biomarkers in predicting CVC in patients with remote myocardial infarction (MI).
- To develop a multifactorial predictive model for CVC in post-MI patients.
Main Methods:
- Serum concentrations of NT-proBNP, ST2, and Ptx-3 were measured in 180 MI patients upon admission.
- Patient outcomes, including MI, cerebrovascular events, and cardiovascular death, were assessed at one year.
- A prognostic model was constructed using these biomarker data and clinical outcomes.
Main Results:
- A mathematical model was developed to predict composite endpoints.
- NT-proBNP and Ptx-3, with ST2 to a lesser extent, showed significant prognostic value for CVC.
- The model achieved a sensitivity of 78.79% and specificity of 86.67% (AUC 0.73).
Conclusions:
- NT-proBNP, ST2, and Ptx-3 enhance the prediction of cardiovascular complications in patients with remote MI.
- The developed multifactorial model offers improved risk assessment for long-term CVC after MI.
Abstract:
Objective To study the prognostic role of current serum biomarkers in patients with myocardial infarction (MI) by constructing a multifactorial model for prediction of cardiovascular complications (CVC) in remote MI. Acute coronary syndrome is a major cause of death and disability in the Russian Federation. Introduction of current biomarkers, such as N-terminal pro-brain natriuretic peptide, stimulating growth factor (ST2), and centraxin-2 (Pentraxin, Ptx-3), provides more possibilities for diagnostics and calculation of risk for CVC.Materials and Methods Concentrations of biomarkers were measured in 180 patients with MI (mean age, 61.4±1.7) upon admission. At one year, specific and composite endpoints were determined (MI, acute cerebrovascular disease, admission for CVD, and cardiovascular death). Based on this information, a prognostic model for subsequent events was developed.Results A mathematical model was created for computing the development of a composite endpoint. In this model, the biomarkers NT-proBNP, Ptx-3 and, to a lesser extent, ST2 demonstrated their prognostic significance in diagnosis of CVC with a sensitivity of 78.79 % and specificity of 86.67 % (area under the curve, AUC 0.73).Conclusion In patients with remote MI, the biomarkers NT-proBNP, ST2, and Ptx-3 improve prediction of CVC.
More Related Videos
Related Concept Videos
Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Acute Coronary Syndrome III: Diagnostic Studies
Coronary Artery Disease I: Introduction
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Myocarditis II: Clinical Features and Diagnostic Tests
Myocarditis III: Medical Management

